drugset / Trial / NCT06916143
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
RandomizedCrossoverOpen-labelBasic science
Summary
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
Timeline
- Start
- 2025-04-08
- Primary completion
- 2025-04-08
- Completion
- 2025-04-08
Outcome
Outcome not reported
Stopped: “Original scientific question rendered moot by the external scientific community”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY4100511 | Unknown | — | Oral |
| Background | Rabeprazole | Small molecule | — | Oral |
Indications
No indication recorded.